1,566
Participants
Start Date
January 21, 2022
Primary Completion Date
May 31, 2023
Study Completion Date
April 24, 2024
T2Resistance Panel
"The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~1. blaKPC~2. blaCTX-M~3. blaNDM / blaVIM / blaIMP~4. blaOXA-48 Group~5. vanA / vanB~6. mecA / mecC~7. AmpC (blaCMY / blaDHA)"
New York University Langone Health, Brooklyn
University of Pittsburgh, Pittsburgh
Johns Hopkins University, Baltimore
Tampa General Hospital, Tampa
University Health, Truman Medical Center, Kansas City
Ochsner Medical Center, New Orleans
University of Texas Health Science Center, Houston
Zuckerberg San Francisco General Hospital, San Francisco
University of Alabama at Birmingham, Birmingham
Rhode Island Hospital, Providence
Lead Sponsor
Biomedical Advanced Research and Development Authority
FED
T2 Biosystems
INDUSTRY